Status:
COMPLETED
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
Lead Sponsor:
University of Chicago
Conditions:
End-Stage Kidney Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys. We propose to treat such patients to decrease ...
Detailed Description
Kidney transplantation is the desired treatment of choice in subjects with end-stage kidney disease (ESRD). The average waiting time for subjects to receive a "deceased donor" kidney transplant is 3-5...
Eligibility Criteria
Inclusion
- Eighteen years or older,
- On the waiting list for a kidney transplant list
- On hemodialysis or peritoneal dialysis
Exclusion
- Pregnant woman
- Patients who need ongoing blood products
- Patients with failed organs having active rejection
- Other therapies to decrease PRA
- Patients listed for multi-organ transplants (other than kidney-pancreas)
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00143741
Start Date
May 1 2005
End Date
July 1 2011
Last Update
January 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637